TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04375800: A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of A

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$724,500

Rescue Site Savings

+$483,000

Unlock Full NCT04375800 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04375800 Rescue Dossier →